Arcutis Biotherapeutics, Inc. (ARQT) financials: revenue, earnings and cash flow
Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$16M, a net margin of -4.3%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $509M and net income $30M.
Free cash flow was -$6M in fiscal 2025 and positive in 0 of the 8 years shown.
The diluted share count rose 10163% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $509M | $376M | $197M | $60M | $4M | $0 | $0 | — | — |
| Gross profit | $464M | $339M | $177M | $55M | $3M | $0 | — | — | — |
| Operating income | $35M | -$12M | -$128M | -$241M | -$302M | -$207M | -$137M | -$43M | -$20M |
| Net income | $30M | -$16M | -$140M | -$262M | -$311M | -$206M | -$136M | -$42M | -$19M |
| EPS (diluted) | $0.21 | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 | $-3.80 | $-22.78 | $-15.53 |
| R&D | $94M | $77M | $76M | $111M | $182M | $146M | $115M | $37M | $18M |
| Revenue growth | — | +91.3% | +229.7% | +1517.1% | — | — | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $60M | -$6M | -$112M | -$247M | -$258M | -$175M | -$113M | -$43M | -$14M |
| Capital spending | -$255000 | -$686000 | -$143000 | -$428000 | -$333000 | -$995000 | -$321000 | -$295000 | $0 |
| Free cash flow | $60M | -$6M | -$112M | -$247M | -$258M | -$176M | -$113M | -$43M | -$14M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $46M | $40M | $42M | $39M | $33M | $24M | $8M | $824000 | $151000 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $221M | $228M | $272M | $410M | $387M | $284M | $101M | $39M |
| Debt | — | $115M | $111M | $206M | $203M | $78M | $5M | $307000 | — |
| Equity | — | $189M | $158M | $89M | $210M | $298M | $271M | -$65M | -$24M |
| Total assets | — | $433M | $349M | $341M | $449M | $408M | $298M | $107M | — |
| Shares (diluted) | 137M | 127M | 121M | 69M | 55M | 49M | 36M | 2M | 1M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 91.2% | 90.2% | 90.3% | 91.6% | 79.5% | — | — | — | — |
| Operating margin | 6.9% | -3.2% | -65.3% | -404.5% | -8183.0% | — | — | — | — |
| Net margin | 5.9% | -4.3% | -71.2% | -439.8% | -8449.8% | — | — | — | — |
| FCF margin | 11.7% | -1.7% | -57.1% | -415.2% | -7000.8% | — | — | — | — |
| ROIC | — | -3.2% | -37.8% | -64.7% | -57.8% | -43.5% | -39.2% | — | — |
| ROE | — | -8.5% | -88.9% | -295.7% | -148.6% | -69.3% | -50.1% | 64.6% | 80.3% |
Frequently asked questions
What is Arcutis Biotherapeutics’s annual revenue?
$376M in fiscal 2025 and $509M over the twelve months to September 30, 2026.
How much profit does Arcutis Biotherapeutics make?
Net income was -$16M in fiscal 2025 (net margin -4.3%).
Is Arcutis Biotherapeutics’s revenue growing?
Yes: revenue rose 91.3% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.